N8-GP
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
N8-GP is a glycoPEGylated long-acting recombinant factor VIII (rfVIII) therapy under development by Novo Nordisk for the treatment of hemophilia A. The PEGylation of N8-GP in the B-domain of fVIII protects it from degradation and clearance by proteolytic enzymes, clearance receptors, and immune effector cells, thereby extending its half-life to 18.4 hours. As a longer-acting drug, N8-GP will act as the successor to NovoEight, which Novo Nordisk launched in 2013.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 N8-GP : Hemophilia
LIST OF FIGURES
8 Figure 49: Datamonitor Healthcare’s drug assessment summary of NovoSeven for hemophilia
12 Figure 60: Datamonitor Healthcare’s drug assessment summary of Nuwiq for hemophilia
LIST OF TABLES
5 Table 1: N8-GP drug profile
7 Table 2: N8-GP Phase III data in hemophilia
13 Table 3: N8-GP sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2016–25
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Rodan + Fields Concealed Prostaglandin Risks From Lash Boost Users – Class... 
Sign up to the